Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts
benzinga | April 01, 2019
The analyst sees the Vyndaqel launch in cardiomyopathy as a catalyst, citing bullish feedback of KOL physicians on immediate conversion of existing U.S. patients. Long-term orphan drug launch analysis suggests scope for market expansion and in turn upside to BofA's above-consensus forecast, the analyst added. Gerberry estimates peak sales of $2 billion for the drug.